Clinical trial
A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.
NCT01498887 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 24, 2011
- Completion date
- December 26, 2015
- Enrollment
- 347 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.
relapsing remitting multiple sclerosis